FR2648047A2 - Polyphenolic product having antiviral activity - Google Patents

Abstract

The invention relates to a use of the polyphenolic derivatives according to Claim 9 of the main Patent Application No. 89/06,282. It comprises the use of these polyphenolic derivatives in pharmaceutical compositions against a virus chosen from the group consisting of AIDS, herpes, chickenpox, influenza A and ECHO 25 viruses. Use in the pharmaceutical industry.

Description

The present invention relates to an application of the product
polyphenolic subject of main patent application no. 89 06282.

 This application claims a polyphenolic product characterized in that it can be obtained by extraction from plant organs by means of volatile polar solvent and by concentration of the extract.

 It also relates to pharmaceutical compositions comprising said product and the use of said product to manufacture anti-viral pharmaceutical compositions.

 During the study subsequent to the filing of this patent application, it was shown that the polyphenolic product described in the main patent application had both exceptional and broad spectrum anti-viral properties. Thus, the present certificate of addition relates to new uses of the said product.

 According to claim 9 of the main patent application, "the use of the product according to one of claims I to 6 of the main patent application to manufacture anti-viral pharmaceutical compositions" gives good results, especially for cases herpes.

 According to the present invention, the use of the products according to one of claims I to 6 for manufacturing anti-viral pharmaceutical compositions gives particularly advantageous results when it comes to combating viruses chosen from the group consisting of the virus. acquired human immunodeficiency syndrome, varicella-zoster herpes, Influenza A and Echo 25.

 It should also be noted that the product according to claims I to 6 of the main patent application exhibits excellent virucidal activity vis-à-vis the human acquired immunodeficiency syndrome virus (HIV1).

 The following examples illustrate this more specific anti-viral activity of the product according to the main patent application.

Example I
Test of water-soluble proceanidols of Cupressus sempervirens on the human acquired immunodeficiency syndrome virus (HIVI).

a) Antiviral effect
The test is carried out on H9 cells infected with successive decimal dilutions of HIVI for 90 minutes.

 After infection of the cells, these are treated with decreasing concentrations of procyanidols at doses lower than the cytotoxicity observed on this cell line (150 pg / ml).

 After 10 days of culture, the cells are centrifuged and the viruses are sought by radioimmunological examination (search for the protein p 24) on the supernatant.

Results
The soluble procyanidols of cypress obtained according to the example
I of main patent application No. 89 06282, provide an inhibition of viral expression of 97% at a concentration of 50 pg / ml.

b) Virucidal effect
The viral suspension (HIV1) is treated for 30 minutes at 37 ° C. with decreasing concentrations of soluble procyanidols of the cypress. Then the H9 cells are infected by successive decimal dilutions of the preceding suspension.

Results
The soluble cypress procyanidols provide a reduction of the viral titer of 1.5 log (initial titer: 3.104) at the concentration of 50 pg / ml, and a reduction of 2.5 log at the concentration of 150 pg / ml.

Example 2
Test of water-soluble procyanidols of Cupressus sempervirens on herpes simplex virus type 11
The antiviral tests were carried out on the herpes simplex virus type 11 implanted on fibroblasts of human embryonic lung.

 The antiviral efficacy of soluble Cupressus sempervirens procyanidols, i.e. the amount of product per well, was determined on a batch of viral suspension corresponding to an infectious dose 50 (LD 50) 2.5.104 viruses per well. (i.e. in 100 pI of medium) which causes the Du 50 to be halved.

 The value found is 3.3 pg / 100 ml.

Example 3
Test of water-soluble procyanidols of Cupressus sempervirens on Varicella zoster virus
The antiviral tests were carried out on the chickenpox and shingles virus implanted on fibroblasts. of human embryonic lung.

 A batch of viral suspension corresponding to an infectious dose of 50 (DIS0) 5,103 viruses per well was determined, the anti-viral efficacy of the soluble procyanidols from Cupressus sempervirens, that is to say the quantity of product per well (c (i.e. 100 pI of medium) which causes the D150 to be halved.

 The value found is 6 pg / 100 ml.

Example 4
Influenza A virus test of water-soluble procyanidols of Cupressus sempervirens
Antiviral tests have been carried out on the Influenza virus
Implanted on human colon adenocarinoma cells.

 The antiviral efficacy of the soluble Cupressus sempervirens procyanidols, that is to say the quantity of product per well, was determined on a batch of viral suspension corresponding to an infectious dose of 50 (DIS0) 7,103 viruses per well. i.e. in 100 PI of medium) which causes a halving of the DISE.

 The value found is 12 pu / 100 ml.

Example 5
Test of water-soluble procyanidols of Cupressus sempervirens on the ECHO 25 virus
The antiviral tests were carried out on the ECHO 25 virus implanted on human embryonic lung fibroblasts
The antiviral efficacy of soluble Cupressus sempervirens procyanidols, i.e. the quantity of product per well, was determined on a batch of viral suspension corresponding to an infectious dose of 50 (D150) 104 viruses per well. i.e. in 100 pI of medium) which causes a halving of the DISO.

 The value found is 31 pu / 100 ml.

Claims (2)

 1. Use according to claim 9 of main patent application No. 89 06282, characterized in that said antiviral pharmaceutical compositions are pharmaceutical compositions against a virus chosen from the group consisting of viruses AIDS, herpes, chickenpox, influenza A and ECHO 25.  2. Use according to claim I, characterized in that said antiviral pharmaceutical composition is a virucidal composition.